{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:26:10Z","timestamp":1790040370990,"version":"4.0.1"},"posted":{"date-parts":[[2026,5,25]]},"group-title":"In Review","reference-count":91,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,5,3]]},"abstract":"<title>Abstract<\/title>\n                <p>Background\n Antipsychotic drugs are increasingly prescribed to children and adolescents (C&amp;A) across a range of neuropsychiatric and neurodevelopmental disorders. Extrapyramidal symptoms (EPS) are well-established adverse effects of antipsychotics in adults, yet evidence in paediatric populations remains limited. This study aimed to quantify the risk of antipsychotic-related EPS in C&amp;A and to explore potential moderating factors.\nMethods\n This PRISMA-compliant systematic review and meta-analysis (PROSPERO; CRD42024564227) searched MEDLINE, Embase, and Web of Science from inception until the 6th of January 2026, for double-blind randomised controlled trials (RCTs) comparing antipsychotics with placebo in individuals aged\u2009&lt;\u200918 years. EPS were assessed through either adverse event reporting or predefined thresholds on validated clinical rating scales and harmonised into a dichotomous outcome (presence vs. absence). Data were extracted by three pairs of independent researchers. Random-effects meta-analyses were conducted to estimate pooled risk ratios (RRs), alongside meta-regression and subgroup analyses examining potential moderators. Risk of bias was assessed using Cochrane Rob2.\nResults\n Thirty-seven RCTs including 5,128 participants (3,141 receiving antipsychotics, 1,987 receiving placebo) were included. Exposure to antipsychotics was associated with a significantly increased risk of EPS compared with placebo (RR\u2009=\u20092.24, 95% CI\u2009=\u20091.71\u20132.93, p\u2009&lt;\u20090.0001), corresponding to a number needed to harm of 7 (95% CI\u2009=\u20095\u201313). The highest risk estimates compared with placebo were observed for ziprasidone (RR\u2009=\u20093.59, 95% CI\u2009=\u20092.03\u20136.35, k\u2009=\u20093), risperidone (RR\u2009=\u20092.84, 95% CI\u2009=\u20091.89\u20134.28, k\u2009=\u200911), and aripiprazole (RR\u2009=\u20092.07, 95% CI\u2009=\u20091.12\u20133.82, k\u2009=\u20099). A higher proportion of female participants was associated with an increased risk of EPS (\u03b2\u2009=\u20090.0136, 95% CI\u2009=\u20090.0019\u20130.0254, p\u2009=\u20090.023), whereas longer treatment duration was associated with reduced risk (\u03b2=\u22120.0349, 95% CI\u2009=\u2009\u2212\u20090.0573\u2013\u22120.0124, p\u2009=\u20090.002). No significant associations were observed for diagnosis, age, ethnicity, antipsychotic exposure, or non-antipsychotic concomitant medication use (all p\u2009&gt;\u20090.05).\nConclusions\n Antipsychotic drugs are associated with EPS in approximately 1 out of 7 C&amp;A with a more than twofold increased risk compared with placebo. The highest risk estimates were observed for ziprasidone, risperidone, and aripiprazole. Careful risk\u2013benefit assessment, tailored prescribing, and systematic monitoring of EPS in routine paediatric clinical practice are warranted.<\/p>","DOI":"10.21203\/rs.3.rs-9601341\/v1","type":"posted-content","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T05:49:22Z","timestamp":1779688162000},"source":"Crossref","is-referenced-by-count":1,"title":["Risk of extrapyramidal symptoms associated with antipsychotic drugs in children and adolescents: a systematic review and meta-analysis of double-blind randomised placebo-controlled trials"],"prefix":"10.21203","author":[{"given":"Joaqu\u00edn","family":"Galva\u00f1","sequence":"first","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Universidad Complutense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Distefano","sequence":"additional","affiliation":[{"name":"Ospedale Maggiore CA Pizzardi, AUSL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Echeverria","sequence":"additional","affiliation":[{"name":"Consorcio Hospitalario Provincial de Castell\u00f3n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e0udia","family":"Aymerich","sequence":"additional","affiliation":[{"name":"King\u2019s College London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Abreg\u00fa-Crespo","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Universidad Complutense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00e9n Mart\u00edn Argila","family":"Lorente","sequence":"additional","affiliation":[{"name":"Hospital Universitario Dr. Rodr\u00edguez Lafora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Cruz","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Universidad Complutense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"L\u00f3pez-Larriba","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Universidad Complutense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Moreno","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Universidad Complutense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Parellada","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Universidad Complutense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso","family":"Arango","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, Universidad Aut\u00f3noma de Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo Salazar","family":"Pablo","sequence":"additional","affiliation":[{"name":"King\u2019s College London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Covadonga M.","family":"D\u00edaz-Caneja","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Universidad Complutense"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"16","key":"ref1","doi-asserted-by":"publisher","first-page":"7964","DOI":"10.1017\/S003329172300212X","article-title":"Randomised controlled trials of antipsychotics for people with autism spectrum disorder: a systematic review and a meta-analysis","volume":"53","author":"Deb S","year":"2023","unstructured":"Deb S, Roy M, Limbu B, Akrout Brizard B, Murugan M, Roy A, et al. Randomised controlled trials of antipsychotics for people with autism spectrum disorder: a systematic review and a meta-analysis. Psychol Med. 2023;53(16):7964\u201372. 10.1017\/S003329172300212X.","journal-title":"Psychol Med"},{"issue":"6","key":"ref2","doi-asserted-by":"publisher","first-page":"e069114","DOI":"10.1136\/bmjopen-2022-069114","article-title":"Use of second-generation antipsychotics in autism spectrum disorder: a systematic review and meta-analysis protocol","volume":"13","author":"Lopes LPN","year":"2023","unstructured":"Lopes LPN, De Oliveira JC, Bergamaschi CDC, Fulone I, Lima EDC, Abe FC, et al. Use of second-generation antipsychotics in autism spectrum disorder: a systematic review and meta-analysis protocol. BMJ Open. 2023;13(6):e069114. 10.1136\/bmjopen-2022-069114.","journal-title":"BMJ Open"},{"issue":"2","key":"ref3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2215-0366(","article-title":"Trends in antipsychotic prescribing to children and adolescents in England: cohort study using 2000\u201319 primary care data","volume":"10","author":"Radoj\u010di\u0107 MR","year":"2023","unstructured":"Radoj\u010di\u0107 MR, Pierce M, Hope H, Senior M, Taxiarchi VP, Trefan L, et al. Trends in antipsychotic prescribing to children and adolescents in England: cohort study using 2000\u201319 primary care data. Lancet Psychiatry. 2023;10(2):119\u201328. 10.1016\/S2215-0366(. 22)00404-7 PubMed PMID: 36638816.","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"ref4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/S2352-4642(24)00098-1","article-title":"Comparative physiological effects of antipsychotic drugs in children and young people: a network meta-analysis","volume":"8","author":"Rogdaki M","year":"2024","unstructured":"Rogdaki M, McCutcheon RA, D\u2019Ambrosio E, Mancini V, Watson CJ, Fanshawe JB, et al. Comparative physiological effects of antipsychotic drugs in children and young people: a network meta-analysis. Lancet Child Adolesc Health. 2024;8(7):510\u201321. 10.1016\/S2352-4642(24)00098-1.","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"ref5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13034-024-00766-4","article-title":"Trends and off-label utilization of antipsychotics in children and adolescents from 2016 to 2021 in China: a real-world study","volume":"18","author":"Zhaojian W","year":"2024","unstructured":"Zhaojian W, Meizhu J, Jun H, Shanshan G, Jiping H, Zhigang Z, et al. Trends and off-label utilization of antipsychotics in children and adolescents from 2016 to 2021 in China: a real-world study. Child Adolesc Psychiatry Ment Health. 2024;18(1):77. 10.1186\/s13034-024-00766-4.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"6","key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0000000000000419","article-title":"Neurological Adverse Effects of Antipsychotics in Children and Adolescents","volume":"35","author":"Garcia-Amador M","year":"2015","unstructured":"Garcia-Amador M, Merch\u00e1n-Naranjo J, Tapia C, Moreno C, Castro-Fornieles J, Baeza I. Neurological Adverse Effects of Antipsychotics in Children and Adolescents. J Clin Psychopharmacol. 2015;35(6). https:\/\/doi.org\/10.1097\/jcp.0000000000000419.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"ref7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1089\/cap.2006.0039","article-title":"Antipsychotic-Related Abnormal Involuntary Movements and Metabolic and Endocrine Side Effects in Children and Adolescents","volume":"17","author":"Laita P","year":"2007","unstructured":"Laita P, Cifuentes A, Doll A, Llorente C, Cort\u00e9s I, Parellada M, et al. Antipsychotic-Related Abnormal Involuntary Movements and Metabolic and Endocrine Side Effects in Children and Adolescents. J Child Adolesc Psychopharmacol. 2007;17(4):487\u2013501. 10.1089\/cap.2006.0039.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"ref8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1186\/s12888-020-02956-8","article-title":"Acceptability, equity, and feasibility of using antipsychotics in children and adolescents with autism spectrum disorder: a systematic review","volume":"20","author":"D\u2019Al\u00f2 GL","year":"2020","unstructured":"D\u2019Al\u00f2 GL, Amato L, Cruciani F, Davoli M, Fulceri F, Minozzi S, et al. Acceptability, equity, and feasibility of using antipsychotics in children and adolescents with autism spectrum disorder: a systematic review. BMC Psychiatry. 2020;20(1):561. 10.1186\/s12888-020-02956-8.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"ref9","doi-asserted-by":"publisher","first-page":"e301287","DOI":"10.1136\/bmjment-2024-301287","article-title":"Guidelines and practice on antipsychotics prescribing and physical health monitoring in children and young people: a cohort study using primary care data","volume":"28","author":"Vinogradova Y","year":"2025","unstructured":"Vinogradova Y, Jack RH, Prasad V, Coupland C, Morriss R, Hollis C. Guidelines and practice on antipsychotics prescribing and physical health monitoring in children and young people: a cohort study using primary care data. BMJ Ment Health. 2025;28(1):e301287. 10.1136\/bmjment-2024-301287.","journal-title":"BMJ Ment Health"},{"issue":"1","key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00787-022-01950-7","article-title":"First do no harm: use off-label antipsychotic medication in children and adolescents with great caution","volume":"31","author":"Hoekstra PJ","year":"2022","unstructured":"Hoekstra PJ, Dietrich A. First do no harm: use off-label antipsychotic medication in children and adolescents with great caution. Eur Child Adolesc Psychiatry. 2022;31(1):1\u20133. 10.1007\/s00787-022-01950-7.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"2","key":"ref11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/wps.20765","article-title":"Safety of 80 antidepressants, antipsychotics, anti-attention-deficit\/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects","volume":"19","author":"Solmi M","year":"2020","unstructured":"Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit\/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020;19(2):214\u201332. 10.1002\/wps.20765.","journal-title":"World Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-025-00730-5","article-title":"Neurological Adverse Effects of Antipsychotic Medication in Children and Young People","volume":"7","author":"Besag FMC","unstructured":"Besag FMC, Vasey MJ, Hollis C, Taylor D. Neurological Adverse Effects of Antipsychotic Medication in Children and Young People. Pediatr Drugs 2026 Jan 7. 10.1007\/s40272-025-00730-5","journal-title":"Pediatr Drugs 2026 Jan"},{"key":"ref13","author":"Rogdaki","unstructured":"Rogdaki et al. \u2013\u20092024 - Comparative physiological effects of antipsychotic.pdf."},{"issue":"3","key":"ref14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/JCP.0b013e3182549259","article-title":"Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents: A Bayesian Meta-Analysis","volume":"32","author":"Cohen D","year":"2012","unstructured":"Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents: A Bayesian Meta-Analysis. J Clin Psychopharmacol. 2012;32(3):309\u201316. 10.1097\/JCP.0b013e3182549259.","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"ref15","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jaac.2023.10.016","article-title":"Umbrella Review: Atlas of the Meta-Analytical Evidence of Early-Onset Psychosis","volume":"63","author":"Salazar De Pablo G","year":"2024","unstructured":"Salazar De Pablo G, Rodriguez V, Besana F, Civardi SC, Arienti V, Mara\u00f1a Garceo L, et al. Umbrella Review: Atlas of the Meta-Analytical Evidence of Early-Onset Psychosis. J Am Acad Child Adolesc Psychiatry. 2024;63(7):684\u201397. 10.1016\/j.jaac.2023.10.016.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"ref16","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.4088\/jcp.v69n0717","article-title":"Metabolic and Hormonal Side Effects in Children and Adolescents Treated With Second-Generation Antipsychotics","volume":"69","author":"Arango C","year":"2008","unstructured":"Arango C, Fraguas D, Merch\u00e1n-Naranjo J, Laita P, Parellada M, Moreno D, et al. Metabolic and Hormonal Side Effects in Children and Adolescents Treated With Second-Generation Antipsychotics. J Clin Psychiatry. 2008;69(7):1165\u201375. 10.4088\/jcp.v69n0717.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"ref17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","article-title":"Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice","volume":"26","author":"Hert MD","year":"2011","unstructured":"Hert MD, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144\u201358. 10.1016\/j.eurpsy.2010.09.011.","journal-title":"Eur Psychiatry"},{"issue":"2\u20133","key":"ref18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the Extrapyramidal Symptom Rating Scale (ESRS)","volume":"76","author":"Chouinard G","year":"2005","unstructured":"Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76(2\u20133):247\u201365. 10.1016\/j.schres.2005.02.013.","journal-title":"Schizophr Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.neubiorev.2017.06.007","article-title":"The clinical and prognostic value of motor abnormalities in psychosis, and the importance of instrumental assessment","volume":"80","author":"Harten PN","year":"2017","unstructured":"Van Harten PN, Walther S, Kent JS, Sponheim SR, Mittal VA. The clinical and prognostic value of motor abnormalities in psychosis, and the importance of instrumental assessment. Neurosci Biobehav Rev. 2017;80:476\u201387. 10.1016\/j.neubiorev.2017.06.007.","journal-title":"Neurosci Biobehav Rev"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"S397","DOI":"10.1016\/S0924-977X(01)00109-2","article-title":"Extrapyramidal side effects are unacceptable","volume":"11","author":"Kane JM","year":"2001","unstructured":"Kane JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol. 2001;11:S397\u2013403. 10.1016\/S0924-977X(01)00109-2.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"ref21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/10401230209149099","article-title":"Extrapyramidal Side Effects of Antipsychotic Treatment: Scope of Problem and Impact on Outcome","volume":"14","author":"Tandon R","year":"2002","unstructured":"Tandon R, Jibson M. Extrapyramidal Side Effects of Antipsychotic Treatment: Scope of Problem and Impact on Outcome. Ann Clin Psychiatry. 2002;14(2):123\u20139. 10.3109\/10401230209149099.","journal-title":"Ann Clin Psychiatry"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/nrn2513","article-title":"Why do many psychiatric disorders emerge during adolescence?","volume":"9","author":"Giedd JN","year":"2008","unstructured":"Giedd JN, Keshavan M, Paus T. Why do many psychiatric disorders emerge during adolescence? Nat Rev Neurosci. 2008;9(12):947\u201357. doi:10.1038\/nrn2513 PubMed PMID: 19002191; PubMed Central PMCID: PMC2762785.","journal-title":"Nat Rev Neurosci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"735625","DOI":"10.3389\/fncir","article-title":"Mesocorticolimbic Dopamine Pathways Across Adolescence: Diversity in Development","volume":"15","author":"Reynolds LM","year":"2021","unstructured":"Reynolds LM, Flores C. Mesocorticolimbic Dopamine Pathways Across Adolescence: Diversity in Development. Front Neural Circuits. 2021;15:735625. 10.3389\/fncir. .2021.735625 PubMed PMID: 34566584; PubMed Central PMCID: PMC8456011.","journal-title":"Front Neural Circuits"},{"issue":"3","key":"ref24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40272-019-00333-x","article-title":"Safety and Tolerability of Antipsychotic Medication in Individuals with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis","volume":"21","author":"Alfageh BH","year":"2019","unstructured":"Alfageh BH, Wang Z, Mongkhon P, Besag FMC, Alhawassi TM, Brauer R, et al. Safety and Tolerability of Antipsychotic Medication in Individuals with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. Pediatr Drugs. 2019;21(3):153\u201367. 10.1007\/s40272-019-00333-x.","journal-title":"Pediatr Drugs"},{"issue":"9","key":"ref25","doi-asserted-by":"publisher","first-page":"e0257129","DOI":"10.1371\/journal.pone.0257129","article-title":"Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies","volume":"16","author":"Ali T","year":"2021","unstructured":"Ali T, Sisay M, Tariku M, Mekuria AN, Desalew A. Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies. PLoS ONE. 2021;16(9):e0257129. 10.1371\/journal.pone.0257129.","journal-title":"PLoS ONE"},{"issue":"9896","key":"ref26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht S","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, \u00d6rey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362. 10.1016\/S0140-6736(13)60733-3.","journal-title":"Lancet"},{"issue":"1","key":"ref27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/schbul\/sbq042","article-title":"Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons","volume":"38","author":"Rummel-Kluge C","year":"2012","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al. Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons. Schizophr Bull. 2012;38(1):167\u201377. 10.1093\/schbul\/sbq042 . PubMed PMID: 20513652; PubMed Central PMCID: PMC3245581.","journal-title":"Schizophr Bull"},{"issue":"8","key":"ref28","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis","volume":"28","author":"Siafis S","year":"2023","unstructured":"Siafis S, Wu H, Wang D, Burschinski A, Nomura N, Takeuchi H, et al. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol Psychiatry. 2023;28(8):3267\u201377. 10.1038\/s41380-023-02203-y.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"ref29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/chi.0b013e31815b5cb1","article-title":"Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes","volume":"47","author":"Correll CU","year":"2008","unstructured":"Correll CU. Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(1):9\u201320. 10.1097\/chi.0b013e31815b5cb1 . PubMed PMID: 18174821.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. 10.1136\/bmj.n71 . PubMed PMID: 33782057.","journal-title":"BMJ"},{"issue":"1","key":"ref31","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13643-017-0644-y","article-title":"Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study","volume":"6","author":"Bramer WM","year":"2017","unstructured":"Bramer WM, Rethlefsen ML, Kleijnen J, Franco OH. Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study. Syst Rev. 2017;6(1):245. 10.1186\/s13643-017-0644-y.","journal-title":"Syst Rev"},{"issue":"6","key":"ref32","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/mds.29392","article-title":"Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations","volume":"38","author":"Martino D","year":"2023","unstructured":"Martino D, Karnik V, Bhidayasiri R, Hall DA, Hauser RA, Macerollo A, et al. Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations. Mov Disord. 2023;38(6):1008\u201326. 10.1002\/mds.29392.","journal-title":"Mov Disord"},{"issue":"3","key":"ref33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","article-title":"Antipsychotic Dose Equivalents and Dose-Years: A Standardized Method for Comparing Exposure to Different Drugs","volume":"67","author":"Andreasen NC","year":"2010","unstructured":"Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic Dose Equivalents and Dose-Years: A Standardized Method for Comparing Exposure to Different Drugs. Biol Psychiatry. 2010;67(3):255\u201362. 10.1016\/j.biopsych.2009.08.040 . PubMed PMID: 19897178; PubMed Central PMCID: PMC3677042.","journal-title":"Biol Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898. 10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"1","key":"ref35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12874-015-0091-1","article-title":"Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies","volume":"15","author":"R\u00f6ver C","year":"2015","unstructured":"R\u00f6ver C, Knapp G, Friede T. Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies. BMC Med Res Methodol. 2015;15(1):99. 10.1186\/s12874-015-0091-1.","journal-title":"BMC Med Res Methodol"},{"key":"ref36","author":"Higgins JPT","year":"2022","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page M et al. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. Version 6.3. London: Cochrane; 2022. Available from: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook"},{"issue":"7168","key":"ref37","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1136\/bmj.317","article-title":"Confidence intervals for the number needed to treat","volume":"317","author":"Altman DG","year":"1998","unstructured":"Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317(7168):1309\u201312. 10.1136\/bmj.317. .7168.1309 PubMed PMID: 9804726.","journal-title":"BMJ"},{"issue":"4","key":"ref38","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S0002-7138(09)61017-7","article-title":"A Comparison of Haloperidol and Behavior Therapy and Their Interaction in Autistic Children","volume":"17","author":"Campbell M","year":"1978","unstructured":"Campbell M, Anderson LT, Meier M, Cohen IL, Small AM, Samit C, et al. A Comparison of Haloperidol and Behavior Therapy and Their Interaction in Autistic Children. J Am Acad Child Adolesc Psychiatry. 1978;17(4):640\u201355. 10.1016\/S0002-7138(09)61017-7.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"ref39","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1177\/1087054720909084","article-title":"A Double-Blind, Randomized Study of Extended-Release Molindone for Impulsive Aggression in ADHD","volume":"25","author":"Ceresoli-Borroni G","year":"2021","unstructured":"Ceresoli-Borroni G, Nasser A, Adewole T, Liranso T, Xu J, Schwabe S, et al. A Double-Blind, Randomized Study of Extended-Release Molindone for Impulsive Aggression in ADHD. J Atten Disord. 2021;25(11):1564\u201377. 10.1177\/1087054720909084.","journal-title":"J Atten Disord"},{"issue":"2","key":"ref40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1089\/cap.2006.0007","article-title":"Randomized Controlled Pilot Study of Quetiapine in the Treatment of Adolescent Conduct Disorder","volume":"18","author":"Connor DF","year":"2008","unstructured":"Connor DF, McLaughlin TJ, Jeffers-Terry M. Randomized Controlled Pilot Study of Quetiapine in the Treatment of Adolescent Conduct Disorder. J Child Adolesc Psychopharmacol. 2008;18(2):140\u201356. 10.1089\/cap.2006.0007.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"ref41","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jaac.2017.06.013","article-title":"Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study","volume":"56","author":"Correll CU","year":"2017","unstructured":"Correll CU, Kohegyi E, Zhao C, Baker RA, McQuade R, Salzman PM, et al. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. J Am Acad Child Adolesc Psychiatry. 2017;56(9):784\u201392. 10.1016\/j.jaac.2017.06.013.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"ref42","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1399-5618.2009.00728.x","article-title":"A double-blind, placebo\u2010controlled pilot study of quetiapine for depressed adolescents with bipolar disorder","volume":"11","author":"DelBello MP","year":"2009","unstructured":"DelBello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M, et al. A double-blind, placebo\u2010controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord. 2009;11(5):483\u201393. 10.1111\/j.1399-5618.2009.00728.x.","journal-title":"Bipolar Disord"},{"issue":"12","key":"ref43","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jaac.2017.10.006","article-title":"Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study","volume":"56","author":"DelBello MP","year":"2017","unstructured":"DelBello MP, Goldman R, Phillips D, Deng L, Cucchiaro J, Loebel A. Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study. J Am Acad Child Adolesc Psychiatry. 2017;56(12):1015\u201325. 10.1016\/j.jaac.2017.10.006.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"ref44","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/00004583-200004000-00021","article-title":"A Double-Blind Pilot Study of Risperidone in the Treatment of Conduct Disorder","volume":"39","author":"Findling RL","year":"2000","unstructured":"Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL. A Double-Blind Pilot Study of Risperidone in the Treatment of Conduct Disorder. J Am Acad Child Adolesc Psychiatry. 2000;39(4):509\u201316. 10.1097\/00004583-200004000-00021.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"ref45","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A Multiple-Center, Randomized, Double-Blind, Placebo-Controlled Study of Oral Aripiprazole for Treatment of Adolescents With Schizophrenia","volume":"165","author":"Findling RL","year":"2008","unstructured":"Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, et al. A Multiple-Center, Randomized, Double-Blind, Placebo-Controlled Study of Oral Aripiprazole for Treatment of Adolescents With Schizophrenia. Am J Psychiatry. 2008;165(11):1432\u201341. 10.1176\/appi.ajp.2008.07061035.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"ref46","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1089\/cap.2012.0029","article-title":"Efficacy, Long-Term Safety, and Tolerability of Ziprasidone in Children and Adolescents with Bipolar Disorder","volume":"23","author":"Findling RL","year":"2013","unstructured":"Findling RL, \u00c7avu\u015f I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK, et al. Efficacy, Long-Term Safety, and Tolerability of Ziprasidone in Children and Adolescents with Bipolar Disorder. J Child Adolesc Psychopharmacol. 2013;23(8):545\u201357. 10.1089\/cap.2012.0029.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"ref47","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1089\/cap.2012.0068","article-title":"Ziprasidone in Adolescents with Schizophrenia: Results from a Placebo-Controlled Efficacy and Long-Term Open-Extension Study","volume":"23","author":"Findling RL","year":"2013","unstructured":"Findling RL, \u00c7avu\u015f I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK, et al. Ziprasidone in Adolescents with Schizophrenia: Results from a Placebo-Controlled Efficacy and Long-Term Open-Extension Study. J Child Adolesc Psychopharmacol. 2013;23(8):531\u201344. 10.1089\/cap.2012.0068.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"01","key":"ref48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4088\/JCP.13m08500","article-title":"A Randomized Controlled Trial Investigating the Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder","volume":"75","author":"Findling RL","year":"2014","unstructured":"Findling RL, Mankoski R, Timko K, Lears K, McCartney T, McQuade RD, et al. A Randomized Controlled Trial Investigating the Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder. J Clin Psychiatry. 2014;75(01):22\u201330. 10.4088\/JCP.13m08500.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"ref49","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/cap.2015.0027","article-title":"Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia","volume":"25","author":"Findling RL","year":"2015","unstructured":"Findling RL, Landbloom RP, Mackle M, Pallozzi W, Braat S, Hundt C, et al. Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia. J Child Adolesc Psychopharmacol. 2015;25(5):384\u201396. 10.1089\/cap.2015.0027.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"10","key":"ref50","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1089\/cap.2016.0160","article-title":"A Double-Blind and Placebo-Controlled Trial of Aripiprazole in Symptomatic Youths at Genetic High Risk for Bipolar Disorder","volume":"27","author":"Findling RL","year":"2017","unstructured":"Findling RL, Youngstrom EA, Rowles BM, Deyling E, Lingler J, Stansbrey RJ, et al. A Double-Blind and Placebo-Controlled Trial of Aripiprazole in Symptomatic Youths at Genetic High Risk for Bipolar Disorder. J Child Adolesc Psychopharmacol. 2017;27(10):864\u201374. 10.1089\/cap.2016.0160.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"ref51","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1089\/cap.2016.0189","article-title":"Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study","volume":"27","author":"Goldman R","year":"2017","unstructured":"Goldman R, Loebel A, Cucchiaro J, Deng L, Findling RL. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. J Child Adolesc Psychopharmacol. 2017;27(6):516\u201325. 10.1089\/cap.2016.0189.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"ref52","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1399-5618.2009.00750.x","article-title":"Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo\u2010controlled study","volume":"11","author":"Haas M","year":"2009","unstructured":"Haas M, DelBello MP, Pandina G, Kushner S, Van Hove I, Augustyns I, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo\u2010controlled study. Bipolar Disord. 2009;11(7):687\u2013700. 10.1111\/j.1399-5618.2009.00750.x.","journal-title":"Bipolar Disord"},{"issue":"6","key":"ref53","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1089\/cap.2008.0144","article-title":"A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Risperidone in Adolescents with Schizophrenia","volume":"19","author":"Haas M","year":"2009","unstructured":"Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Risperidone in Adolescents with Schizophrenia. J Child Adolesc Psychopharmacol. 2009;19(6):611\u201321. 10.1089\/cap.2008.0144.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"ref54","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/cap.2006.16.541","article-title":"ADouble-Blind Placebo-Controlled Pilot Study of Olanzapine in Childhood\/Adolescent Pervasive Developmental Disorder","volume":"16","author":"Hollander E","year":"2006","unstructured":"Hollander E, Wasserman S, Swanson EN, Chaplin W, Schapiro ML, Zagursky K, et al. ADouble-Blind Placebo-Controlled Pilot Study of Olanzapine in Childhood\/Adolescent Pervasive Developmental Disorder. J Child Adolesc Psychopharmacol. 2006;16(5):541\u20138. 10.1089\/cap.2006.16.541.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"ref55","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s10578-016-0704-x","article-title":"Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study","volume":"48","author":"Ichikawa H","year":"2017","unstructured":"Ichikawa H, Mikami K, Okada T, Yamashita Y, Ishizaki Y, Tomoda A, et al. Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study. Child Psychiatry Hum Dev. 2017;48(5):796\u2013806. 10.1007\/s10578-016-0704-x.","journal-title":"Child Psychiatry Hum Dev"},{"issue":"1","key":"ref56","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/CHI.0b013e3181900404","article-title":"Olanzapine Versus Placebo in Adolescents With Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"48","author":"Kryzhanovskaya L","year":"2009","unstructured":"Kryzhanovskaya L, Schulz SC, Mcdougle C, Frazier J, Dittmann R, Robertson-Plouch C, et al. Olanzapine Versus Placebo in Adolescents With Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Trial. J Am Acad Child Adolesc Psychiatry. 2009;48(1):60\u201370. 10.1097\/CHI.0b013e3181900404.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"ref57","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1089\/cap.2006.16.575","article-title":"Risperidone in Preschool Children with Autistic Spectrum Disorders: An Investigation of Safety and Efficacy","volume":"16","author":"Luby J","year":"2006","unstructured":"Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M, et al. Risperidone in Preschool Children with Autistic Spectrum Disorders: An Investigation of Safety and Efficacy. J Child Adolesc Psychopharmacol. 2006;16(5):575\u201387. 10.1089\/cap.2006.16.575.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"ref58","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1089\/cap.2010.0100","article-title":"Young Mania Rating Scale Line Item Analysis in Pediatric Subjects with Bipolar I Disorder Treated with Aripiprazole in a Short-Term, Double-Blind, Randomized Study","volume":"21","author":"Mankoski R","year":"2011","unstructured":"Mankoski R, Zhao J, Carson WH, Mathew SJ, Forbes RA. Young Mania Rating Scale Line Item Analysis in Pediatric Subjects with Bipolar I Disorder Treated with Aripiprazole in a Short-Term, Double-Blind, Randomized Study. J Child Adolesc Psychopharmacol. 2011;21(4):359\u201364. 10.1089\/cap.2010.0100.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"11","key":"ref59","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder","volume":"48","author":"Marcus RN","year":"2009","unstructured":"Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, et al. A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110\u20139. 10.1097\/CHI.0b013e3181b76658.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"ref60","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/08830738060210060801","article-title":"Risperidone in Children With Autism: Randomized, Placebo-Controlled, Double-Blind Study","volume":"21","author":"Nagaraj R","year":"2006","unstructured":"Nagaraj R, Singhi P, Malhi P. Risperidone in Children With Autism: Randomized, Placebo-Controlled, Double-Blind Study. J Child Neurol. 2006;21(6):450\u20135. 10.1177\/08830738060210060801.","journal-title":"J Child Neurol"},{"issue":"6","key":"ref61","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder","volume":"124","author":"Owen R","year":"2009","unstructured":"Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, et al. Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder. Pediatr. 2009;124(6):1533\u201340. 10.1542\/peds.2008-3782.","journal-title":"Pediatr"},{"issue":"2","key":"ref62","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","article-title":"Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial","volume":"37","author":"Pandina GJ","year":"2007","unstructured":"Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F. Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial. J Autism Dev Disord. 2007;37(2):367\u201373. 10.1007\/s10803-006-0234-7.","journal-title":"J Autism Dev Disord"},{"issue":"3","key":"ref63","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1176\/appi.ajp.163.3.402","article-title":"Double-Blind, Placebo-Controlled Study of Risperidone Maintenance Treatment in Children and Adolescents With Disruptive Behavior Disorders","volume":"163","author":"Reyes M","year":"2006","unstructured":"Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens MA, Randomized. Double-Blind, Placebo-Controlled Study of Risperidone Maintenance Treatment in Children and Adolescents With Disruptive Behavior Disorders. Am J Psychiatry. 2006;163(3):402\u201310. 10.1176\/appi.ajp.163.3.402.","journal-title":"Am J Psychiatry"},{"key":"ref64","article-title":"Risperidone in Children with Autism and Serious Behavioral Problems","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2002","unstructured":"Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in Children with Autism and Serious Behavioral Problems. N Engl J Med. 2002.","journal-title":"N Engl J Med"},{"key":"ref65","unstructured":"Research Units on Pediatric Psychopharmacology Autism Network. Risperidone Treatment of Autistic Disorder: Longer-Term Benefits and Blinded Discontinuation After 6 Months. Am J Psychiatry. 2005 Jul 1. Located at: world. 10.1176\/appi.ajp.162.7.1361"},{"issue":"1","key":"ref66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1089\/cap.2021.0013","article-title":"Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study","volume":"32","author":"Saito T","year":"2022","unstructured":"Saito T, Sugimoto S, Sakaguchi R, Nakamura H, Ishigooka J. Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. J Child Adolesc Psychopharmacol. 2022;32(1):12\u201323. 10.1089\/cap.2021.0013.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"ref67","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","article-title":"Ziprasidone Treatment of Children and Adolescents With Tourette\u2019s Syndrome: A Pilot Study","volume":"39","author":"Sallee FR","year":"2000","unstructured":"Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, et al. Ziprasidone Treatment of Children and Adolescents With Tourette\u2019s Syndrome: A Pilot Study. J Am Acad Child Adolesc Psychiatry. 2000;39(3):292\u20139. 10.1097\/00004583-200003000-00010.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"ref68","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1089\/cap.2016.0026","article-title":"Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette\u2019s Disorder in Children and Adolescents","volume":"27","author":"Sallee F","year":"2017","unstructured":"Sallee F, Kohegyi E, Zhao J, McQuade R, Cox K, Sanchez R, et al. Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette\u2019s Disorder in Children and Adolescents. J Child Adolesc Psychopharmacol. 2017;27(9):771\u201381. 10.1089\/cap.2016.0026.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"ref69","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","article-title":"A placebo-controlled trial of risperidone in Tourette syndrome","volume":"60","author":"Scahill L","year":"2003","unstructured":"Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60(7):1130\u20135. 10.1212\/01.WNL.0000055434.39968.67.","journal-title":"Neurology"},{"issue":"5","key":"ref70","doi-asserted-by":"publisher","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders","volume":"114","author":"Shea S","year":"2004","unstructured":"Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, et al. Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders. Pediatrics. 2004;114(5):e634\u201341. 10.1542\/peds.2003-0264-F.","journal-title":"Pediatrics"},{"issue":"12","key":"ref71","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.biopsych.2011.06.021","article-title":"Double-Blind Study of Paliperidone Extended-Release in Treatment of Acute Schizophrenia in Adolescents","volume":"70","author":"Singh J","year":"2011","unstructured":"Singh J, Robb A, Vijapurkar U, Nuamah I, Hough DA, Randomized. Double-Blind Study of Paliperidone Extended-Release in Treatment of Acute Schizophrenia in Adolescents. Biol Psychiatry. 2011;70(12):1179\u201387. 10.1016\/j.biopsych.2011.06.021.","journal-title":"Biol Psychiatry"},{"issue":"10","key":"ref72","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1176\/appi.ajp.2007.06111932","article-title":"Olanzapine Versus Placebo in the Treatment of Adolescents With Bipolar Mania","volume":"164","author":"Tohen M","year":"2007","unstructured":"Tohen M, Kryzhanovskaya L, Carlson G, DelBello M, Wozniak J, Kowatch R, et al. Olanzapine Versus Placebo in the Treatment of Adolescents With Bipolar Mania. Am J Psychiatry. 2007;164(10):1547\u201356. 10.1176\/appi.ajp.2007.06111932.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"ref73","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S2215-0366(25)00043-4","article-title":"Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference","volume":"12","author":"Ward C","year":"2025","unstructured":"Ward C, Pejovi\u0107 Milovan\u010devi\u0107 M, Kohegyi E, Hefting N, Aurang C, Chen D, et al. Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference. Lancet Psychiatry. 2025;12(5):345\u201354. 10.1016\/S2215-0366(25)00043-4.","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"ref74","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1089\/cap.2024.0118","article-title":"Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-Label Extension in Children and Adolescents","volume":"35","author":"Ward C","year":"2025","unstructured":"Ward C, Childress A, Martinko K, Chen D, Larsen KG, Shah A, et al. Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-Label Extension in Children and Adolescents. J Child Adolesc Psychopharmacol. 2025;35(4):194\u2013201. 10.1089\/cap.2024.0118.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9896","key":"ref75","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht S","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, \u00d6rey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362. 10.1016\/S0140-6736(13)60733-3.","journal-title":"Lancet"},{"issue":"9","key":"ref76","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40263-016-0367-y","article-title":"Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis","volume":"30","author":"Bernagie C","year":"2016","unstructured":"Bernagie C, Danckaerts M, Wampers M, De Hert M. Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis. CNS Drugs. 2016;30(9):807\u201318. 10.1007\/s40263-016-0367-y.","journal-title":"CNS Drugs"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"656370","DOI":"10.1155\/2014\/656370","article-title":"Second-Generation Antipsychotics and Extrapyramidal Adverse Effects","volume":"2014","author":"Divac N","year":"2014","unstructured":"Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-Generation Antipsychotics and Extrapyramidal Adverse Effects. Biomed Res Int. 2014;2014:656370. doi:10.1155\/2014\/656370 PubMed PMID: 24995318; PubMed Central PMCID: PMC4065707.","journal-title":"Biomed Res Int"},{"issue":"2","key":"ref78","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaac.2024.07.920","article-title":"Systematic Review and Network Meta-Analysis: Efficacy and Safety of Antipsychotics vs Antiepileptics or Lithium for Acute Mania in Children and Adolescents","volume":"64","author":"Vita G","year":"2025","unstructured":"Vita G, N\u00f6hles VB, Ostuzzi G, Barbui C, Tedeschi F, Heuer FH, et al. Systematic Review and Network Meta-Analysis: Efficacy and Safety of Antipsychotics vs Antiepileptics or Lithium for Acute Mania in Children and Adolescents. J Am Acad Child Adolesc Psychiatry. 2025;64(2):143\u201357. 10.1016\/j.jaac.2024.07.920.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"ref79","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.euroneuro.2018.03.008","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis","volume":"28","author":"Krause M","year":"2018","unstructured":"Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, et al. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. Eur Neuropsychopharmacol. 2018;28(6):659\u201374. 10.1016\/j.euroneuro.2018.03.008.","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41537-021-00170-3","article-title":"Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro study","volume":"7","author":"Hoekstra S","year":"2021","unstructured":"Hoekstra S, Bartz-Johannessen C, Sinkeviciute I, Reitan SK, Kroken RA, L\u00f8berg EM, et al. Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro study. NPJ Schizophr. 2021;7:39. 10.1038\/s41537-021-00170-3 . PubMed PMID: 34408155; PubMed Central PMCID: PMC8373883.","journal-title":"NPJ Schizophr"},{"issue":"10","key":"ref81","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1038\/s41380-020-0660-5","article-title":"The genetics of drug-related movement disorders, an umbrella review of meta-analyses","volume":"25","author":"Burg NC","year":"2020","unstructured":"Van Der Burg NC, Al Hadithy AFY, Van Harten PN, Van Os J, Bakker PR. The genetics of drug-related movement disorders, an umbrella review of meta-analyses. Mol Psychiatry. 2020;25(10):2237\u201350. 10.1038\/s41380-020-0660-5.","journal-title":"Mol Psychiatry"},{"issue":"9","key":"ref82","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.euroneuro.2014.07.001","article-title":"Extrapyramidal symptoms during treatment of first schizophrenia episode: Results from EUFEST","volume":"24","author":"Rybakowski JK","year":"2014","unstructured":"Rybakowski JK, Vansteelandt K, Remlinger-Molenda A, Fleischhacker WW, Kahn RS, Peuskens J. Extrapyramidal symptoms during treatment of first schizophrenia episode: Results from EUFEST. Eur Neuropsychopharmacol. 2014;24(9):1500\u20135. 10.1016\/j.euroneuro.2014.07.001.","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.neubiorev.2021.11.027","article-title":"A systematic review of the prognostic value of motor abnormalities on clinical outcome in psychosis","volume":"132","author":"Pieters LE","year":"2022","unstructured":"Pieters LE, Nadesalingam N, Walther S, van Harten PN. A systematic review of the prognostic value of motor abnormalities on clinical outcome in psychosis. Neurosci Biobehav Rev. 2022;132:691\u2013705. 10.1016\/j.neubiorev.2021.11.027.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"ref84","doi-asserted-by":"publisher","first-page":"e301184","DOI":"10.1136\/bmjment-2024-301184","article-title":"Prevalence of spontaneous movement disorders (dyskinesia, parkinsonism, akathisia and dystonia) in never-treated patients with chronic and first-episode psychosis: a systematic review and meta-analysis","volume":"27","author":"Kalniunas A","year":"2024","unstructured":"Kalniunas A, James K, Pappa S. Prevalence of spontaneous movement disorders (dyskinesia, parkinsonism, akathisia and dystonia) in never-treated patients with chronic and first-episode psychosis: a systematic review and meta-analysis. BMJ Ment Health. 2024;27(1):e301184. 10.1136\/bmjment-2024-301184 . PubMed PMID: 39313255; PubMed Central PMCID: PMC11418527.","journal-title":"BMJ Ment Health"},{"issue":"8","key":"ref85","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis","volume":"28","author":"Siafis S","year":"2023","unstructured":"Siafis S, Wu H, Wang D, Burschinski A, Nomura N, Takeuchi H, et al. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol Psychiatry. 2023;28(8):3267\u201377. 10.1038\/s41380-023-02203-y.","journal-title":"Mol Psychiatry"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.euroneuro.2025.06.007","article-title":"Extrapyramidal symptoms as early clinical predictors in first-episode schizophrenia and schizophreniform disorder: findings from the OPTiMiSE trial","volume":"98","author":"Galva\u00f1 J","year":"2025","unstructured":"Galva\u00f1 J, Su\u00e1rez-Campayo J, Ayora M, Gil S, Winter-van Rossum I, Berger G, et al. Extrapyramidal symptoms as early clinical predictors in first-episode schizophrenia and schizophreniform disorder: findings from the OPTiMiSE trial. Eur Neuropsychopharmacol. 2025;98:35\u201345. 10.1016\/j.euroneuro.2025.06.007.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"ref87","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41537-022-00270-8","article-title":"Extrapyramidal symptoms predict cognitive performance after first-episode psychosis","volume":"8","author":"Lindgren M","year":"2022","unstructured":"Lindgren M, Therman S, Avellan A, From T, Hietala J, Holm M, et al. Extrapyramidal symptoms predict cognitive performance after first-episode psychosis. Schizophr (Heidelb). 2022;8(1):64. 10.1038\/s41537-022-00270-8 . PubMed PMID: 35927423; PubMed Central PMCID: PMC9352759.","journal-title":"Schizophr (Heidelb)"},{"issue":"07","key":"ref88","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1017\/S0033291708004716","article-title":"Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review","volume":"39","author":"Pappa S","year":"2009","unstructured":"Pappa S, Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol Med. 2009;39(07):1065. 10.1017\/S0033291708004716.","journal-title":"Psychol Med"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.euroneuro.2020.07.003","article-title":"Movement disorder and sensorimotor abnormalities in schizophrenia and other psychoses - European consensus on assessment and perspectives","volume":"38","author":"Walther S","year":"2020","unstructured":"Walther S, Van Harten PN, Waddington JL, Cuesta MJ, Peralta V, Dupin L, et al. Movement disorder and sensorimotor abnormalities in schizophrenia and other psychoses - European consensus on assessment and perspectives. Eur Neuropsychopharmacol. 2020;38:25\u201339. 10.1016\/j.euroneuro.2020.07.003.","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref90","unstructured":"NICE. National Institute for Health and Care Excellence. Antisocial behaviour and conduct disorders in children and young people: recognition and management. [Internet]. NICE; 2013 [cited 2026 Mar 1]. Available from: https:\/\/www.nice.org.uk\/guidance\/cg158"},{"key":"ref91","unstructured":"NICE. National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management [Internet]. NICE. 2013 [cited 2026 Mar 1]. Available from: https:\/\/www.nice.org.uk\/guidance\/cg155"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9601341\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9601341\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T05:49:24Z","timestamp":1779688164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9601341\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":91,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9601341\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,5,25]]},"subtype":"preprint"}}